Aligos Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALGS research report →
About the company
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB).
- CEO
- Lawrence Blatt
- IPO
- 2020
- Employees
- 70
- HQ
- South San Francisco, CA, US
Price Chart
- Market Cap
- $34.59M
- P/E
- -0.64
- P/S
- 7.35
- P/B
- 1.83
- EV/EBITDA
- -0.10
- Div Yield
- 0.00%
- Gross Margin
- 89.03%
- Op Margin
- -2033.39%
- Net Margin
- -1919.68%
- ROE
- -139.47%
- ROIC
- -212.93%
- Revenue
- $2.19M · -44.59%
- Net Income
- $-24,193,000 · 81.56%
- EPS
- $-2.45 · 88.30%
- Op Income
- $-87,985,000
- FCF YoY
- -2.56%
- 52W High
- $13.69
- 52W Low
- $4.80
- 50D MA
- $5.73
- 200D MA
- $7.84
- Beta
- 2.26
- Avg Volume
- 217.24K
Get TickerSpark's AI analysis on ALGS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 25, 26 | Preston Heather | other | 5,860 |
| Jun 25, 26 | Chavez Margarita | other | 5,860 |
| Jun 25, 26 | Martell Bridget A | other | 5,860 |
| Jun 25, 26 | Scopa James Paul | other | 5,860 |
| Jun 25, 26 | Nuechterlein Carole | other | 5,860 |
| Jun 25, 26 | Hirth Peter | other | 5,860 |
| Mar 9, 26 | Aneja Nikhil | other | 9,450 |
| Mar 9, 26 | Calhoun Lesley Ann | other | 37,485 |
| Mar 9, 26 | BLATT LAWRENCE | other | 105,840 |
| Jan 29, 26 | Aneja Nikhil | other | 3,800 |
Our ALGS coverage
Recent articles, reports, and earnings notes.
No research on ALGS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALGS report →Similar companies
Peers in the same neighborhood.